All In Biotech

Drug Trial Radar · NCT01425008

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

149

Actual

Start

Sep 15, 2011

Primary completion

Apr 11, 2017

Study completion Oct 16, 2018

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Aug 29, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.

Conditions

  • Melanoma
  • Metastatic Melanoma
  • Solid Tumor
  • Neoplasm

Interventions

  • MLN2480Drug

    Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and DeathsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
  2. Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)Time frame: Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])
  3. Number of Participants With TEAEs Related to Physical Examination FindingsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
  4. Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
  5. Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) FindingsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
  6. Eastern Cooperative Oncology Group (ECOG) Performance ScoreTime frame: at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
  7. Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or UrinalysisTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    San Francisco, California

  • Site not named

    Denver, Colorado

  • Site not named

    Augusta, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    New York, New York

  • Site not named

    Easton, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    San Antonio, Texas

  • Site not named

    Lakewood, Washington

  • Site not named

    Bristol, Avon, United Kingdom

  • Site not named

    Cambridge, Cambridgeshire, United Kingdom

  • Site not named

    Chelmsford, Essex, United Kingdom

  • Site not named

    London, Greater London, United Kingdom

  • Site not named

    Manchester, Greater Manchester, United Kingdom

  • Site not named

    Oxford, Oxfordshire, United Kingdom

  • Site not named

    Newcastle upon Tyne, Tyne & Wear, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.